Peripheral and cerebral atherothrombosis and cardiovascular events in different vascular territories: Insights from the Framingham Study

Current Atherosclerosis Reports

Volumn 8, Issue 4, 2006, Pages 317-323

  Kannel, William B ^a   Wolf, Philip A ^b  

^a FRAMINGHAM HEART STUDY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DISEASE PREDISPOSITION; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEMOSTASIS; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; LIFESTYLE; OBESITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; STANDARDIZATION; STROKE;

ATHEROSCLEROSIS; CEREBROVASCULAR DISORDERS; COSTS AND COST ANALYSIS; HUMANS; INCIDENCE; PREVALENCE; RISK ASSESSMENT; THROMBOSIS;

EID: 33745912764     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0010-3     Document Type: Article

References (41)

1. Cupples LA, D'Agostino RB: Survival Following Initial Cardiovascular Events. The Framingham Study. 30-year follow-up. Section 35. NIH Publication No. 88-2909, 1988.
2. Kannel WB: Global cardiovascular risk evaluation. In Preventive Cardiology. A Practical Approach, edn 2. Edited by Wong ND, Black HR, Gardin JM. New York: McGraw-Hill; 2005:1-21.
3. 2 NHLBI Chart Book on Cardiovascular Lung and Blood Diseases.
4. Hiatt WR: Medical treatment of peripheral arterial disease. N Engl J Med 2001, 344:1608-1621.
5. Thom TJ: Stroke mortality trends: an international perspective. Ann Epidemiol 1993, 3:509-518.
6. American Heart Association 2004 Heart Disease and Stroke Statistics-2004 Update. Dallas, TX: American Heart Association; 2004.
7. Hylek EM, Go AS, Chang Y, et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019-1026.
8. Kannel WB, McGee DL: Update on some epidemiologic features of intermittent claudication. J Am Geriatr Soc 1985, 33:13-18.
9. Kannel WB: Risk factors for atherosclerotic cardiovascular outcomes in different vascular territories. J Cardiovasc Risk 1994, 1:1-7.
10. Murabito JM, Evans JC, D'Agostino RB, et al.: Temporal trends of intermittent claudication from 1950-1999. Am J Epidemiol 2005, 162:430-437.
11. Hackam DG, Goodman SG, Annand SS: Management of risk in peripheral artery disease: Recent therapeutic advances. Am Heart J 2005, 150:35-40.
12. Sacco RL, Benjamin EJ, Broderick JP, et al.: Risk factors. Stroke 1997, 28:1507-1517.
13. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
14. Benjamin EJ, Plehn JF, D'Agostino RB, et al.: Mitral annular calcification and risk of stroke in an elderly cohort. N Engl J Med 1992, 327:374-379.
15. Kannel WB, Wolf PA, Verter J: Manifestations of coronary disease predisposing to stroke. JAMA 1983. 250:2942-2946.
16. Sacco RL, Foulkes MA, Mohr JP, et al.: Determinants of early recurrence of cerebral infarction: the Stroke Data Bank. Stroke 1989, 20:983-989.
17. Sacco RL, Wolf PA, Kannel WB, McNamara PM: Survival and recurrence following stroke: the Framingham Study. Stroke 1982, 13:290-295.
18. Sacco RL, Shi T, Zamanillo MC, Kargman DE: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stoke Study. Neurology 1994, 44:626-634.
19. Kannel WB: Epidemiologic relation of cardiovascular disease among different vascular territories. In Atherothrombosis and Coronary Artery Disease, edn 2. Edited by Fuster V, Topol EJ, Nabel EG: Philadelphia: Lippincott Williams & Wilkins; 2005:1493-1496.
20. Wolf PA, Kannel WB, Sorlie P, McNamara P: Asymptomatic carotid bruit and risk of stroke. The Framingham Study. JAMA 1981, 245:1442-1445.
21. Kase CS, Wolf PA, Chodosh EH, et al.: Prevalence of silent stroke in patients presenting with initial stroke: the Framingham Study. Stroke 1989, 20:850-852.
22. Chodosh EH, Foulkes MA, Kase CS, et al.: Silent stroke in the NINCDS Stroke Data Bank. Neurology 1998, 38:1674-1679.
23. Manolio TA, Kronmal RA, Burke GL, et al.: Magnetic resonance abnormalities and cardiovascular disease in older adults. Stroke 1994, 25:318-327.
24. Vermeer SF, Prins ND, Den Heijer T, et al.: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003, 348:1215-1222.
25. Giele JL, Witkamp TD, Mali WP, van der Graaf Y: Silent brain infarcts in patients with manifest vascular disease. Stroke 2004, 35:742.
26. Murabito J M, Evans JC, Larson MG, et al.: The Ankle-Brachial Index in the elderly and risk of stroke, coronary disease and death. The Framingham Study. Arch Intern Med 2003, 163:1939-1942.
27. Franklin SS, Kahn SA, Wong ND, et al.: Is pulse pressure useful in predicting risk for coronary heart disease? Circulation 1999, 100:354-360.
28. O'Leary DH, Anderson KM, Wolf PA, et al.: Cholesterol and carotid atherosclerosis. The Framingham Study. Ann Epidemiol 1992, 2:147-153.
29. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events trial investigators. N Engl J Med 1996, 335:1001-1029.
30. Wolf PA, D'Agostino RB, Bonita R, Belanger AJ: Cigarette smoking as a risk factor for stroke. The Framingham study. JAMA 1988, 259:1025-1029.
31. Fowler B, Jamrozik K, Norman P, Allen Y: Prevalence of peripheral arterial disease; persistence of excess risk in former smokers. Aust NZ J Pub Health 2002, 26:219-224.
32. Reaven GM: Syndrome X: 6 years later. J Intern Med 1995, 736:13-22.
33. Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005, 56:45-62.
34. Najarian RM, Sullivan LM, Wilson PW, et al.: Impact of the metabolic syndrome compared to diabetes as a risk factor for stroke. Arch Inern Med 2006, 166:106-111.
35. Wilson PW, D'Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
36. Brand RJ, Rosenman RH, Sholtz RI, Friedman M: Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham Study. Circulation 1976, 53:348-355.
37. Leaverton PE, Sorlie PD, Kleinman JC, et al.: Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis 1987, 40:775-784.
38. McGee D, Gordon T: The results of the Framingham Study applied to four other US-based studies of cardiovascular disease. In The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, section 31. Edited by Kannel WB, Gordon T. US Dept of Health Education and Welfare publication No. 76-1083. Bethesda, MD: US Government Printing Office; 1976.
39. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 1991, 22:312-318.
40. Murabito JM, D'Agostino RB, Silbershatz H, Wilson PW: Intermittent claudication: a risk profile from the Framingham Study. Circulation 1997, 96:44-49.
41. Murabito JM, Evans JC, Nieto K, et al.: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002, 143:961-965.